ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis & Investment Frameworks
ARS Pharmaceuticals, Inc. (SPRY) stock analysis on Invetso. Review ARS Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
ARS Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
ARS Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $429.61M
- Revenue: $84.28M
- ROE: -256.67%
- ROIC: -114.61%
- Dividend Yield: N/A
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
ARS Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes ARS Pharmaceuticals, Inc. (SPRY) across the following frameworks:
- ARS Pharmaceuticals, Inc. 10Y Growth Potential
- ARS Pharmaceuticals, Inc. Scenario Analysis
- ARS Pharmaceuticals, Inc. Risks & Opportunities
- ARS Pharmaceuticals, Inc. Economic Moat
- ARS Pharmaceuticals, Inc. Business Model
- ARS Pharmaceuticals, Inc. Management
- ARS Pharmaceuticals, Inc. SWOT Analysis
- ARS Pharmaceuticals, Inc. Porter's 5 Forces
- ARS Pharmaceuticals, Inc. PESTLE Analysis
- ARS Pharmaceuticals, Inc. ESG Analysis